Urgent

Latex (natural rubber latex) allergy

Occupational / perioperative allergy · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Two distinct reactions to natural rubber latex: immediate IgE-mediated (type I, Hevea proteins; urticaria → anaphylaxis) and delayed type IV contact dermatitis (to rubber accelerator chemicals). All sensitised patients need latex-safe precautions. High-risk groups: healthcare workers, spina bifida / multiple surgeries, atopic patients, certain occupations. DRAFT for clinician review.

Red flags

  • Intraoperative/periprocedural hypotension or bronchospasm of unknown cause (consider latex), especially in spina bifida, multiple-surgery or healthcare-worker patients
  • Progressive urticaria/angioedema/airway involvement after latex contact

Assessment

Differential diagnosis

  • Type I: other causes of anaphylaxis / contact urticaria; perioperative anaphylaxis from another agent
  • Type IV: allergic contact dermatitis to accelerators; irritant contact dermatitis from glove occlusion/handwashing
  • Latex-fruit syndrome (banana, kiwi, avocado, chestnut cross-reactivity)

Investigations

  • History of reactions temporally linked to latex (gloves, balloons, condoms, dental dams, catheters)
  • US: serum latex-specific IgE (only FDA-cleared test; no skin-test extract available in US)
  • Europe: skin-prick extract available
  • Patch testing to distinguish type IV contact dermatitis

Management

  • Acute type I reaction/anaphylaxis — treat per anaphylaxis protocol AND remove the latex source
  • Establish a latex-SAFE environment (non-latex/synthetic gloves, latex-free equipment, 'one-stick rule' through latex vial stoppers)
  • Flag the chart and apply an allergy band
  • Counsel avoidance of latex-containing products and cross-reactive foods
  • Prescribe epinephrine autoinjector for type-I patients
  • Refer to allergy / occupational health

Drugs & doses

Acute type I reaction / anaphylaxis — treat per anaphylaxis protocol (IM epinephrine) and remove latex. Self-injectable epinephrine for all with a history of systemic reaction.
Type IV contact dermatitis — avoidance + topical corticosteroid (per contact dermatitis management); prescription mupirocin if a topical antibiotic is needed and there is bacitracin/neomycin co-allergy.
No effective preventive pharmacotherapy; immunotherapy and anti-IgE are investigational and not routine.

Disposition

After a systemic reaction — observe, then discharge with epinephrine autoinjector + action plan, medical-alert bracelet, latex-avoidance advice (including pre-procedure notification) and allergy referral. Contact dermatitis — avoidance + topical steroid, dermatology/occupational-health referral.

Complications & pitfalls

  • Anaphylaxis (including perioperative/IV exposure via latex vial stoppers)
  • Occupational asthma/rhinoconjunctivitis from aerosolised glove powder
  • Chronic hand contact dermatitis
  • Latex-fruit cross-reactive food anaphylaxis
  • Resensitisation with ongoing exposure

Exam pearls

  • Manage ALL latex-sensitised patients (even those who had only contact dermatitis) as at risk for type I reactions
  • Goal is latex-'safe', not 'latex-free' (a completely latex-free environment is not achievable)
  • Injection through a latex vial stopper can trigger reactions in the highly allergic — use synthetic-stopper vials or the 'one-stick rule'
  • Cross-reactive foods: banana, kiwi, avocado, chestnut, papaya, potato, tomato
  • Latex-specific IgE can persist ≥5 years — continue precautions even if later testing is negative

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.